GSK Expects Nearly to Double Cancer Drugs in Clinical Trials Next Year
GSK expects nearly to double the number of cancer medicines in clinical trials next year, according to oncology research head Hesham Abdullah.
GSK expects nearly to double the number of cancer medicines in clinical trials next year, according to oncology research head Hesham Abdullah.